Search clinical trials for: Open Label Extension

Total 10907 results

Novartis Pharmaceuticals

Recruiting

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (REPLENISH-EXT)

Polymyalgia Rheumatica

Australia
GB002, Inc.

Not yet recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Pulmonary Arterial Hypertension

United States
argenx
Iqvia Pty Ltd

Recruiting

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome (Rho plus)

Primary Sjögren's Syndrome

Belgium, Hungary, Poland
ACADIA Pharmaceuticals Inc.

Not yet recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Alzheimer's Disease Psychosis

United States
PharmAust Ltd
Macquarie University, Australia; Calvary Health Care Bethlehem

Recruiting

An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease

Motor Neuron Disease

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Thyroid Eye Disease, TED

China
Opsidio, LLC
Innovaderm Research Inc.

Recruiting

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
TWi Biotechnology, Inc.

Recruiting

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex

United States, Taiwan, Australia, Philippines
Mineralys Therapeutics Inc.

Recruiting

Open-Label Extension Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Uncontrolled Hypertension

Hypertension

United States
argenx
Iqvia Pty Ltd

Recruiting

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)

Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

United States
Novartis Pharmaceuticals

Recruiting

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) (OLE)

Hyperlipoproteinemia (a)

Germany
Inhibrx, Inc.

Not yet recruiting

Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema (ELEVAATE OLE)

Emphysema | Alpha 1-Antitrypsin Deficiency
Ichnos Sciences SA

Not yet recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia
Pathalys Pharma
Launch Therapeutics

Recruiting

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 (PATH-2)

Secondary Hyperparathyroidism | End Stage Kidney Disease

United States, Bulgaria, Portugal, Spain, Poland, Serbia
Pathalys Pharma
Launch Therapeutics

Recruiting

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 (PATH-1)

Secondary Hyperparathyroidism | End-stage Kidney Disease (ESKD)

United States, Bulgaria, Portugal, Spain, Poland, Serbia
Humanitas Mirasole SpA
KU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaborators

Recruiting

Open Label Extension of TUDCA-ALS Study (TUDCA-ALS OLE)

Amyotrophic Lateral Sclerosis

Germany, France, Netherlands, Italy, United Kingdom, Belgium, Ireland
Tang-Du Hospital

Recruiting

Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis (tMG-E)

Myasthenia Gravis, Generalized

China
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Malaysia, Argentina, Thailand, Poland, Japan, Netherlands, Chile, Canada
Kezar Life Sciences, Inc.

Recruiting

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Autoimmune Hepatitis

United States
Haukeland University Hospital

Recruiting

NOPARK Open Label Extension Study

Safety Issues

Norway
Inmune Bio, Inc.

Recruiting

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies

Australia, Canada
Contera Pharma A/S

Not yet recruiting

Open-Label Extension Study of ASTORIA

Dyskinesias
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, Italy, China, Hungary, Czechia, Turkey, Argentina, Colombia, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
KalVista Pharmaceuticals, Ltd.

Recruiting

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Bulgaria, France, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, North Macedonia, Poland, Spain, United Kingdom, Australia, Germany, South Africa, Austria, Portugal, Slovakia, Romania, Canada, Saudi Arabia, Japa...
Ichnos Sciences SA

Recruiting

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia
Belgian Inflammatory Bowel Disease Research and...
Janssen Cilag N.V./S.A.

Recruiting

An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study (REScUE-OLE)

Crohn Disease

Belgium
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE)

Asthma

United States, Australia, Canada, France, Germany, Italy, Japan, Poland, Spain, China, Czechia, Hungary, Taiwan, United Kingdom
Lawson Health Research Institute
Seagen Inc.

Recruiting

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Diffuse Cutaneous Systemic Sclerosis

Canada
Pfizer

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Hemophilia A | Hemophilia B

Hong Kong, Spain, Serbia, Turkey, United States, China, Mexico, South Africa, India, Japan, Croatia, Korea, Republic of, Oman, Taiwan, Italy, Canada, France
M.D. Anderson Cancer Center

Recruiting

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Myeloma

United States
Madrigal Pharmaceuticals, Inc.

Recruiting

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Non-Alcoholic Fatty Liver Disease

United States, Puerto Rico
GB002, Inc., a wholly owned subsidiary of Gossamer...

Recruiting

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Australia, Spain, Czechia, France, Germany, United Kingdom, Belgium
ES Therapeutics Australia Pty Ltd

Recruiting

Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

Drug Resistant Epilepsy

Australia
Novartis Pharmaceuticals

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

Autoimmunity, Inflammation

China, United States, Spain, Czechia, Mexico, Bulgaria, Colombia, Brazil, Russian Federation, Guatemala, South Africa, Poland, India, Malaysia, Korea, Republic of, Greece
Lupin Ltd.

Recruiting

Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.

Myotonic Disorders

France
Novartis Pharmaceuticals

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Japan, Korea, Republic of, United States, Denmark, France, Taiwan, Belgium, Israel, Thailand, Germany, India, Czechia, Malaysia, Argentina, Singapore, China, Australia, Norway, Turkey, United Kingdom, Brazil, Hong Kong, Netherlands, C... and more
Pfizer
Pfizer

Recruiting

Open-Label Extension of Voxelotor

Sickle Cell Disease

Lebanon, United Kingdom, United States, Nigeria, Egypt
MediciNova

Recruiting

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (COMBAT-ALS)

Amyotrophic Lateral Sclerosis

United States, Canada
Erydel

Recruiting

Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study (OLE-IEDAT)

Ataxia Telangiectasia

United States, Australia, Belgium, Germany, India, Italy, Poland, Spain, Tunisia
Cassava Sciences, Inc.

Enrolling by invitation

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Alzheimer Disease

United States, Canada, Puerto Rico
Agenus Inc.

Active, not recruiting

Study of AGEN1571 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States
MapLight Therapeutics

Enrolling by invitation

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

United States, Australia
Soleno Therapeutics, Inc.

Completed

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

Prader-Willi Syndrome

United States, United Kingdom
United Therapeutics

Enrolling by invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Cardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Connective Tissue Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract Disease

United States, Spain, Australia, Taiwan, Canada, Singapore, United Kingdom, Italy, Germany, China, Mexico, Argentina, Korea, Republic of, Austria, Greece, Sweden, Portugal, Belgium, Brazil, Bulgaria, Chile, Croatia, Czechia, Denmark, Fr... and more
Ra Pharmaceuticals, Inc.

Active, not recruiting

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Generalized Myasthenia Gravis

United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LILAC™)

Rett Syndrome

United States
Novartis Pharmaceuticals

Completed

CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Heart Failure

United States, Italy, Croatia, India, Japan, Poland, Spain, Taiwan, Austria, Korea, Republic of, Germany, Lebanon, Thailand, Canada, Bulgaria, Russian Federation, Turkey, Switzerland, Argentina, Hungary, Portugal, Finland, South Africa and more
Amgen

Terminated

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study (RECAST SLE OLE)

Systemic Lupus Erythematosus

United States, Spain, Serbia, Mexico, Poland, Greece, Argentina, India, Taiwan
SK Life Science, Inc.

Enrolling by invitation

Cenobamate Open-Label Extension Study for YKP3089C025

Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy

United States, Bulgaria, Czechia, Hungary, Poland, Slovakia, Ukraine
Xentria, Inc.

Enrolling by invitation

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States

Search clinical trials for: Open Label Extension

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations